These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16128675)

  • 1. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study.
    Vahedi H; Merat S; Rashidioon A; Ghoddoosi A; Malekzadeh R
    Aliment Pharmacol Ther; 2005 Sep; 22(5):381-5. PubMed ID: 16128675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study.
    Kuiken SD; Tytgat GN; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2003 May; 1(3):219-28. PubMed ID: 15017494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM; Meyers NL; Hickling RI
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome.
    Bundeff AW; Woodis CB
    Ann Pharmacother; 2014 Jun; 48(6):777-84. PubMed ID: 24651166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Chang L; Chey WD; Drossman D; Losch-Beridon T; Wang M; Lichtlen P; Mareya S
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1114-1122. PubMed ID: 27669680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
    Hamatani T; Fukudo S; Nakada Y; Inada H; Kazumori K; Miwa H
    Aliment Pharmacol Ther; 2020 Aug; 52(3):430-441. PubMed ID: 32583907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
    Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
    Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW; Stanghellini V; Geraint M; Halphen M
    Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.